User menu

Brivaracetam disposition in mild to severe hepatic impairment.

Bibliographic reference Stockis, Armel ; Sargentini-Maier, Maria Laura ; Horsmans, Yves. Brivaracetam disposition in mild to severe hepatic impairment.. In: The Journal of Clinical Pharmacology, Vol. 53, no.6, p. 633-641 (2013)
Permanent URL http://hdl.handle.net/2078.1/136274
  1. Bialer Meir, Johannessen Svein I., Levy René H., Perucca Emilio, Tomson Torbjörn, White H. Steve, Progress report on new antiepileptic drugs: A summary of the Tenth Eilat Conference (EILAT X), 10.1016/j.eplepsyres.2010.09.001
  2. Kenda Benoit M., Matagne Alain C., Talaga Patrice E., Pasau Patrick M., Differding Edmond, Lallemand Bénédicte I., Frycia Anne M., Moureau Florence G., Klitgaard Henrik V., Gillard Michel R., Fuks Bruno, Michel Philippe, Discovery of 4-Substituted Pyrrolidone Butanamides as New Agents with Significant Antiepileptic Activity, 10.1021/jm030913e
  3. Zona Cristina, Pieri Massimo, Carunchio Irene, Curcio Livia, Klitgaard Henrik, Margineanu Doru Georg, Brivaracetam (ucb 34714) inhibits Na+ current in rat cortical neurons in culture, 10.1016/j.eplepsyres.2009.09.024
  4. Matagne A, Margineanu D-G, Kenda B, Michel P, Klitgaard H, Anti-convulsive and anti-epileptic properties of brivaracetam (ucb 34714), a high-affinity ligand for the synaptic vesicle protein, SV2A : Anticonvulsive properties of brivaracetam, 10.1038/bjp.2008.198
  5. Kaminski, Epilepsia., 50, 5 (2009)
  6. Kasteleijn-Nolst Trenite D.G.A., Genton P., Parain D., Masnou P., Steinhoff B. J., Jacobs T., Pigeolet E., Stockis A., Hirsch E., Evaluation of brivaracetam, a novel SV2A ligand, in the photosensitivity model, 10.1212/01.wnl.0000271385.85302.55
  7. French J. A., Costantini C., Brodsky A., von Rosenstiel P., , Adjunctive brivaracetam for refractory partial-onset seizures: A randomized, controlled trial, 10.1212/wnl.0b013e3181ec7f7f
  8. Van Paesschen Wim, Hirsch Edouard, Johnson Martin, Falter Ursula, von Rosenstiel Philipp, Efficacy and tolerability of adjunctive brivaracetam in adults with uncontrolled partial-onset seizures: A phase IIb, randomized, controlled trial : Brivaracetam in Partial-Onset Seizures, 10.1111/j.1528-1167.2012.03598.x
  9. Rolan Paul, Sargentini-Maier Maria Laura, Pigeolet Etienne, Stockis Armel, The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after multiple increasing oral doses in healthy men, 10.1111/j.1365-2125.2008.03158.x
  10. Sargentini-Maier Maria Laura, Rolan Paul, Connell John, Tytgat Dominique, Jacobs Tom, Pigeolet Etienne, Riethuisen Jean-Michel, Stockis Armel, The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after single increasing oral doses in healthy males, 10.1111/j.1365-2125.2006.02829.x
  11. Sargentini-Maier M. L., Espie P., Coquette A., Stockis A., Pharmacokinetics and Metabolism of 14C-Brivaracetam, a Novel SV2A Ligand, in Healthy Subjects, 10.1124/dmd.107.017129
  12. Lacroix, Epilepsia., 48, 333 (2007)
  13. von Rosenstiel Philipp, Perucca Emilio, Brivaracetam, The Treatment of Epilepsy ISBN:9781444316667 p.447-457, 10.1002/9781444316667.ch35
  14. Verbeeck Roger K., Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction, 10.1007/s00228-008-0553-z
  15. Molino Gianpaolo, Cavanna Alberto, Avagnina Paolo, Ballar� Marco, Torchio Mauro, Hepatic clearance ofd-sorbitol : Noninvasive test for evaluating functional liver plasma flow, 10.1007/bf01296143
  16. Pugh R. N. H., Murray-Lyon I. M., Dawson J. L., Pietroni M. C., Williams Roger, Transection of the oesophagus for bleeding oesophageal varices, 10.1002/bjs.1800600817
  17. KERR WILLIAM C., STOCKWELL TIM, Understanding standard drinks and drinking guidelines : Understanding standard drinks and drinking guidelines, 10.1111/j.1465-3362.2011.00374.x
  18. Echizen Hirotoshi, Ohta Yasuo, Shirataki Hiromichi, Tsukamoto Kazuhisa, Umeda Noritsugu, Oda Toshitsugu, Ishizaki Takashi, Effects of Subchronic Treatment with Natural Human Interferons on Antipyrine Clearance and Liver Function in Patients with Chronic Hepatitis, 10.1002/j.1552-4604.1990.tb03621.x
  19. Baririan Narin??, Van Obbergh Luc, Desager Jean-Pierre, Verbeeck Roger K, Wallemacq Pierre, Starkel Peter, Horsmans Yves, Alfentanil-Induced Miosis as a Surrogate Measure of Alfentanil Pharmacokinetics in Patients with Mild and Moderate Liver Cirrhosis : , 10.2165/00003088-200746030-00006
  20. BROCKMOLLER J, THOMSEN T, WITTSTOCK M, COUPEZ R, LOCHS H, ROOTS I, Pharmacokinetics of levetiracetam in patients with moderate to severe liver cirrhosis (Child-Pugh classes A, B, and C): Characterization by dynamic liver function tests, 10.1016/j.clpt.2005.02.003
  21. Sargentini-Maier Maria Laura, Sokalski Antoni, Boulanger Pierre, Jacobs Tom, Stockis Armel, Brivaracetam Disposition in Renal Impairment, 10.1177/0091270011431457
  22. Strolin Benedetti Margherita, Whomsley Rhys, Nicolas Jean-Marie, Young Colin, Baltes Eug�ne, Pharmacokinetics and metabolism of 14 C-levetiracetam, a new antiepileptic agent, in healthy volunteers, 10.1007/s00228-003-0655-6
  23. Nicolas J.- M., Chanteux H., Rosa M., Watanabe S., Stockis A., Effect of Gemfibrozil on the Metabolism of Brivaracetam In Vitro and in Human Subjects, 10.1124/dmd.112.045328
  24. FRYE R, ZGHEIB N, MATZKE G, CHAVESGNECCO D, RABINOVITZ M, SHAIKH O, BRANCH R, Liver disease selectively modulates cytochrome P450–mediated metabolism, 10.1016/j.clpt.2006.05.006
  25. Areberg Johan, Christophersen Jacob Strøyer, Poulsen Mette Nøhr, Larsen Frank, Molz Karl-Heinz, The pharmacokinetics of escitalopram in patients with hepatic impairment, 10.1208/aapsj080102
  26. Piqu?? Josep M., Feu Faust, de Prada Gloria, R??hss Kerstin, Hasselgren G??ran, Pharmacokinetics of Omeprazole Given by Continuous Intravenous Infusion to Patients with Varying Degrees of Hepatic Dysfunction : , 10.2165/00003088-200241120-00004
  27. Marcellin P., De Bony F., Garret C., Altman C., Boige V., Castelnau C., Laurent-Puig P., Trinchet J. C., Rolan P., Chen C., Mamet J. P., Bidault R., Influence of cirrhosis on lamotrigine pharmacokinetics : Cirrhosis and lamotrigine pharmacokinetics, 10.1046/j.1365-2125.2001.01389.x
  28. Patsalos Philip N, Clinical Pharmacokinetics of Levetiracetam : , 10.2165/00003088-200443110-00002
  29. FDA http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm072123.pdf